Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Earnings for Xeris Biopharma Holdings, Inc. (XERS)
Earnings in 2024 (TTM): $-63,504,000
According to Xeris Biopharma Holdings, Inc.'s latest financial reports the company's current earnings (TTM) are $-63,504,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Xeris Biopharma Holdings, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-63,504,000 | $-62,255,000 |
| 2023 | $-96,084,000 | $-94,660,000 |
| 2022 | $-96,084,000 | $-94,660,000 |
| 2021 | $-122,725,000 | $-122,725,000 |
| 2020 | $-91,250,000 | $-91,140,000 |
| 2019 | $-60,080,000 | $-60,080,000 |
| 2018 | $-26,554,000 | $-26,554,000 |
| 2017 | $-13,209,000 | $-13,209,000 |